SignalSilence® Survivin siRNA II #6546
 |
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
|
Catalog # | |
Size & Concentration | | Price(£) | |
Qty | |
|
| |||||||||
| |||||||||
| Please contact us for bulks/custom orders/drug discovery applications | |||||||||
Western Blotting
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Fluorescein Conjugate) #6201 (-) or SignalSilence® Survivin siRNA II (+), using Survivin (71G4B7E) Rabbit mAb #2808 and α-Tubulin (11H10) Rabbit mAb #2125. Survivin (71G4B7E) Rabbit mAb confirms silencing of survivin expression and α-Tubulin (11H10) Rabbit mAb is used to control for loading and specificity of survivin siRNA.
Description
SignalSilence® Survivin siRNA II from Cell Signaling Technology (CST) allows the researcher to specifically inhibit survivin expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce protein expression by western analysis.
Directions for Use
CST recommends transfection with 100 nM Survivin siRNA II 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Background
Survivin is a 16 kDa anti-apoptotic protein highly expressed during fetal development and cancer cell malignancy (1). Survivin binds and inhibits caspase-3, controlling the checkpoint in the G2/M-phase of the cell cycle through inhibiting apoptosis and promoting cell division (2,3). This regulatory process requires the phosphorylation of survivin at Thr34 by p34 cdc2 kinase (4). Gene targeting using a Thr34 phosphorylation-defective survivin mutant, as well as antisense survivin, has been shown to inhibit tumor growth (5,6).
- Reed, J.C. and Reed, S.I. (1999) Nature Cell Biol. 1, 199-200.
- Li, F. et al. (1998) Nature 396, 580-584.
- Li, F. et al. (1999) Nat. Cell Biol. 1, 461-466.
- O'Connor, D.S. et al. (2000) Proc. Natl. Acad. Sci. USA 97, 13103-13107.
- Olie, R.A. et al. (2000) Cancer Res. 60, 2805-2809.
- Grossman, D. et al. (2001) Proc. Natl. Acad. Sci. USA 98, 635-640.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
Companion Products- 6201 SignalSilence® Control siRNA (Fluorescein Conjugate)
- 6568 SignalSilence® Control siRNA (Unconjugated)
- 6351 SignalSilence® Survivin siRNA I
- 6547 SignalSilence® Survivin siRNA Kit
- 2808 Survivin (71G4B7) Rabbit mAb
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.